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In LEW rats treated daily with variable doses of 
FK506 for 14 days and weekly thereafter, successful 
intestinal transplantation from fully allogeneic BN do-
nors never was complicated by fatal GVHD. In contrast, 
with LEW-to-BN transplantation, rejection was diffi-
cult to control and GVHD developed after the end of the 
daily treatment. However, FK506 in high daily doses 
continued after the initial 14-day course could prevent 
this GVHD or even reverse it after allowing its onset. 
Further experiments did not clarify why the BN rat was 
an "easy" donor and "difficult" recipient. In unaltered 
animals the lymphocyte population of normal LEW rats 
had a higher proportion of T cells, fewer B cells, and a 
lower CD4:CD8 ratio than normal BN rats. However, 
one-way MLR reactions of the BN and LEW combina-
tions were generally similar in either direction and not 
affected differently by the addition of FK506 to the 
medium. The two-way lymphocyte traffic from graft to 
host lymphoid organs and vice versa also was similar 
with BN-to-LEW and LEW-to-BN models. The BN rat 
may be a useful tool to investigate inadequately ex-
plained mechanisms of GVHD. 
The prerequisites defined by Billingham (1) for the devel-
opment of graft-versus-host disease are the presence of mature 
immunologically competent cells in the graft, sufficient time 
for these cells to react before they are rejected by the host, and 
important histocompatibility antigens in the recipient that are 
lacking in the transplant. Because of the large lymphoid com-
ponent of the intestine, histopathologic findings in recipients 
of canine intestine (2, 3) and multivisceral grafts that included 
intestine (4) were thought but not proved to be explained by 
GVHD. Subsequently, GVHD and its consequences were delin-
eated clearly by Monchik and Russell (5) in genetically con-
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trolled rat experiments in which semiallogeneic small bowel 
transplantation was from parent strain to F 1 hybrid offspring 
who were incapable of rejecting the grafts but subject to their 
attack. Although the rat models emphasized the peril of a host-
graft immunologic imbalance if this favored the graft, such 
laboratory experiments overstated the clinical threat of GVHD, 
which in patients has been minor compared with rejection (6-
8). 
A commonly used rat strain combination for experimental 
multi visceral and intestinal transplantation has been the fully 
allogeneic Brown Norway-to-Lewis model, in which the dom-
inant immunologic response was rejection, either without (9) 
or with immunosuppression (10). Under FK506, chronic sur-
vival was the rule. In these rats (10) and humans (8, 11), the 
lymphoreticular cells of the intestine and its mesentery were 
largely replaced with those of the recipient, usually without 
GVHD. However, if the direction of the BN-LEW rat trans-
plantation is reversed, using the LEW strain as donor instead 
of recipient, we have observed that both rejection and GVHD 
are resistant to immunosuppression, making it difficult to 
achieve survival or graft acceptance (12). In an effort to explain 
this difference, we have examined LEW -to-BN intestinal trans-
plantation in greater detail, with particular attention to the 
distribution of the cells that have been shown in rats (10, 12), 
swine (13), and humans (7,8, 11) to emigrate from intestinal 
grafts. 
MATERIALS AND METHODS 
Inbred male LEW (RTll) and BN (RTI n) rats weighing 200-300 gm 
were obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN), 
and were maintained in conventional animal facilities with standard 
diet. 
In Vitro Immunologic Assessment (Unaltered Animals) 
To see if there were obvious differences in the cellular immune 
apparatus of the BN and LEW strains, in vitro studies were made of 
lymphocytes from the various lymphoid organs (Table 1) of sacrificed 
unaltered animals. The Peyer's patches were individually dissected and 
excised from the ileum and jejunum. The lymphoid tissues were minced 
into RPMI-1640 (Gibco, Grand Island, NY) followed by vigorous 
mechanical agitation and filtration. Peripheral blood mononuclear cells 
were isolated by centrifugation over a Ficoll-Hypaque gradient. 
Lymphocyte subsets (flow cytometry). After washing with RPMI, the 
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TABLE 1. Lymphocyte subsets (% total) in diffeIent tissues of normal LEW and BN rats 
StJain T"JSSUe HBSS W3/'lfJ (CIM) OX8(CDS) OX 19 Bcell (IgG) 
LEW (n = 5) Thymus 0.72±1.07 91.02±4.33 88.06±8.06 96.30±2.23 2.98±O.74 
Spleen 4.15±1.72 35.10±5.61 19.10±2.97 48.26±10.09 42.88±5.54 
Cervical LN 0.70±0.52 49.32±5.54 21.70±3.25 72.50±6.06 28.18±6.49 
Mesenteric LN 0.56±O.32 5O.32±4.57 15.88±3.39 69.64±5.93 32.28±1.63 
Blood 0.78±O.31 5O.62±L72 21.78±2.94 66.00±3.86 21.6O±5.21 
Peyer's patches 0.96±O.90 7.SS±2.07 3.85±2.33 10A3±2.52 8L45±2.47 
BN (n = 5) Thymus 0.6±O.8 92.90±0.47 87.7B±2.02 95.70±2.09 3.92±1.28 
Spleen 5.66±3.38 29.38±3.38 11.00±3.84* 30..20±2.36* 64.88±2.29* 
CervicalLN 1.2O±O.27 58.80±5.19 10.2O±1.86* 63.00±3.92 36.63±3.06 
Mesenteric LN 1.10±0.96 49.00+-2.37 6.98±3.64* 53.08±2.90* 46.13±3.03* 
Blood l.8O±1.59 «.98±6.58 6.42±2.89* 47.76±5.98* «.23±5.75* 
Peyer's patches 1.30±1.06 13.96±5.35 2.60±0.28 15.93±6.55 77.03±5.52 
* P < 0.01 versus LEW (Student's t test). 
lymphocytes were resuspended in Hank's balanced salt solution (Gibco) 
with 1.0% bovine serum albumin and 0.1 % NaNa at a concentration of 
10X1{f 1m!. The purified lymphocytes were studied with a panel of 
monoclonal antibodies (Sera Laboratory, Westbury, NY) that included 
W3/25 (CD4, 1:4(0), OXS (CDS, 1:1(0), OX19 (pan T cell, 1:4(0), and 
antirat IgG (B cell, 1:75). Lymphocytes from Peyer's patches, spleen, 
thymus, mesenteric LN, cervical LN, and peripheral blood were stained 
with the diluted monoclonal antibodies using FITC-conjugated goat 
antimouse IgG, (1:400, Sera Laboratory) as a secondary antibody. The 
samples were analyzed on a F ACSean Flow Cytometer and the per-
centage of cells staining positive with each monoclonal antibody was 
recorded. 
Mixed lymphocyte reaction. One-way MLR was performed (BN stim-
ulator -+ LEW responder or LEW -+ BN) with mesenteric node 
lymphocytes. Triplicate cultures of 1.75XlW responder cells and 3X1(f 
irradiated (2000 rad) stimulator cells were cultured in a final volume 
of 0.2 ml RPMI supplemented with 25 mM HEPES buffer, 5X10-5 M 
2-mercaptoethanol, 2 mM L-glutamine, penicillin (50 U/ml), strepto-
mycin (50 J,Ig/ml), and 10% heat-inactivated normal rat serum. Cultures 
were incubated in a humidified atmosphere of 5% CO. in air for 5 days 
at 37°C. One )lCi of 3H -thymidine was added to each well 16 hr before 
the termination of the culture. Cultures were harvested with multiple 
sample harvester and 3H-thymidine uptake was determined by liquid 
scintillation spectrometry. 
In addition, the effect on the MLR response of varying concentra-
tions of FK506 in the culture was tested. The results were expressed 
as percentage of inhibition by using the following formula: 
f hib·· ( c.p.m. with drugs) lOO percentage 0 in ItlOn = 1 - . h dru x 
c.p.m. Wit out g 
Experimental and Therapeutic Procedures 
Orthotopic small intestine transplantation with portal drainage was 
performed with a previously described technique (12) from BN to LEW 
and from LEW to BN. The entire donor small intestine from the 
ligament of Treitz to the ileocecal valve was isolated with a vascular 
pedicle consisting of the superior mesenteric artery on a segment of 
aorta and the superior mesenteric vein in continuity with the portal 
vein. After donor heparinization (300 U), the graft was perfused with 
10 ml of cold lactated Ringer's solution via the aorta. The lumen was 
washed with cold neomycin sulfate solution. End-to-side vascular an-
astomoses were performed with 10-0 Novafil suture between graft aorta 
and recipient infrarenal aorta, and between graft portal vein and 
recipient portal vein. The entire recipient small intestine was resected. 
Intestinal continuity was restored by proximal and distal intestinal 
anastomoses using 6-0 continuous or interrupted silk suture. 
The animals were given 20 mg/day cefamandole nafate for 3 post-
operative days. Regular rat chow was started from the day after 
transplantation. Body weight and activity were checked every day for 
the first 2 weeks and then twice or more a week. For immunosuppres-
sion, intramuscular FK506, dissolved in HCO-60 and D-mannitol ear-
rier solvent (gift from Fujisawa Pharmaceutical Co., Osaka, Japan), 
was diluted in normal saline and injected into the thigh daily starting 
on the day of operation and continuing for at least 13 more days. In 
selected groups, variable doses were continued or started thereafter. 
Pathologic Studies 
For frozen and formalin fixation, mesenteric lymph nodes and Pey-
er's patches from the jejunum and ileum were obtained from the grafts. 
Recipient liver, spleen, mesenteric lymph nodes, duodenum, thymus, 
peripheral lymph nodes, and skin (ear and tongue) were obtained at 
autopsy or sacrifice. The tissues were stained with H&E, and L-21-6 
mouse anti-LEW class II monoclonal antibody, kindly provided by Dr. 
A. Yagihashi and Dr. Y. Iwaki (Departments of Surgery and Pathology, 
University of Pittsburgh) as described before (10). 
In addition, bits of fresh tissue were obtained from the graft and 
recipient lymphoid organs for removal and purification of lymphocytes 
as was described for unaltered animals. Donor and recipient cells were 
identified with affinity-purified biotinylated rat monoclonal antibody 
163 (rat IgG2b), which is specific for the RTl.N antigen on LEW, or 
monoclonal antibody 42 (rat IgG2a), which is specific for the RT1.AD 
antigen on BN (14) (kindly provided by Dr. H. W. Kunz, University of 
Pittsburgh, Department of Pathology). The monoclonal antibodies 
were diluted (1:200) and mixed with 50 )lI of lymphocyte suspension 
and incubated for 45 min at 4°C. The suspensions were washed once 
with HBSS with BSA and NaN3• Then, FITC-conjugated streptavidin 
(1:100, Pharmingen, San Diego, CA) was added for another 10 min at 
4°C. Finally, cells were washed twice and fixed in 0.3 ml saline con-
taining 1.0% paraformaldehyde. The samples were analyzed using a 
FACScan Flow Cytometer. The percentage of cells stained positive 
with each monoclonal antibody was determined. 
Statistical Analysis 
Results were expressed as mean ± SO. Results were compared using 
an unpaired Student's t test. A value of less than 0.01 was considered 
significant. 
RESULTS 
In Vitro Studies (Unaltered Animals) 
Lymphocyte subsets. The thymus in both rat strains was 
similar. The contribution ofT cells (OX19) to the lymphocyte 
population was smaller in the BN rats than in LEW in all of 
the individual lymphoid organs except Peyer's patches, in which 
it was greater (Table 1). The differences were significant in the 
mesenteric lymph nodes, spleen, and blood. CD4 (W3/25) was 
similar in both strains and the disparity in T cells was primarily 
of the CD8 (OX8) specificity. B lymphocytes were commensu-
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rately increased throughout the lymphoid organs except the 
thymus and Peyer's patches in BN compared with LEW (Table 
1). 
MLR. The one-way MLR was not different with BN -to-LEW 
than with LEW-to-BN (data not shown). The inhibition of 
MLR by FK506 was not significantly different in the two strain 
directions except at a concentration of 0.5 ng/ml (Fig. 1), where 
the proliferative response of BN-to-LEW stimulator cells was 
more suppressed than the response of LEW-to-BN stimulator 
cells although not quite to the level of significance (P=0.0184). 
Studies After Transplantation 
BN-to-LEW: no treatment. It was previously reported that 
untreated animals died of rejection after a median survival of 
10.5 days (12). 
Low-dose FK506. Median survival was increased to 42 days 
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FIGURE 1. Inhibition of one-way MLR (using mesenteric lympho-
cytes) with different concentrations of FK506. LEW responder-BN 
stimulator (open circle); BN responder-LEW stimulator (closed circle). 
with 0.15 mg/kg/day for 14 days, but the animals developed 
the skin flush of GVHD (biopsy-confirmed) in the ears and 
face (especially periorbital) after 6 and 9 days. The GVHD was 
self-resolving and disappeared in 4 to 5 days (Table 2). Graft 
rejection was the ultimate cause of death. 
High-dose FK506. With 0.64 mg/kg/day for 14 days, all 
animals survived more than 100 days without GVHD (Table 
2). Although allowing long survival, this 2-week treatment has 
been shown before to result eventually in chronic graft rejection 
(12). When the 14-day treatment was supplemented with 
weekly injections of the same dose, it was previously shown 
that all animals survived without chronic rejection (Table 2). 
LEW-to-BN: no treatment. Unmodified BN recipients (group 
5) rejected LEW intestine (histopathologically proved) in 11 to 
13 days (Table 2). These animals had signs of temporary GVHD 
after 6 to 9 days, similar to LEW recipients of BN under low-
dose FK506 (group 2). Four additional animals were sacrificed 
for flow cytometry studies, 2 at 5 and 2 at 9 days. At 5 days, 
lymphocytes of donor phenotype were detectable in the recipi-
ents' blood and lymphoid organs, but in the 2 animals killed at 
9 days, these were not detectable (Table 3). The cytometry 
findings were concordant with the appearance and spontaneous 
disappearance of clinical GVHD in the untreated animals stud-
ied for survival. 
Low-dose FK506. When FK506 was given at 0.15 mg/kg/day 
for 14 days (Table 2, group 6), FK506 increased median survival 
to 22.5 days, but 5 of 6 of these BN recipients of LEW grafts 
showed clinical GVHD. The GVHD was temporary (beginning 
after 8 to 12 days) in 2 animals who died ultimately of rejection 
at 32 days. In the other 3 (Table 2) the GVHD was fatal after 
20 to 23 days; their intestinal grafts were essentially normal. 
The sixth animal died of volvulus and distal anastomotic ob-
struction. This was thought to be an immunologic complication 
rather than technical because it was commonly seen in lightly 
treated animals in BN-to-LEW and especially in LEW-to-BN 
transplantation (Table 2). 
High-dose FK506. At FK506 doses of .64 mg/kg/day or 1.0 
mg/kg/day for 14 days with or without supplemental weekly 
TABLE 2. Survival after small bowel transplantation from BN to LEW and from LEW to BN 
Group Donor Recipient FK506 treatment N Survival (days)" Median Ileus Temporary Fatal GVHD GVHD 
1) (12) BN LEW 6 9, 9, 10, 11, 12, 14 10.5 0 0 0 
2 BN LEW 0.15 mg/kg X 14 8 9,b 10,b 36,41, 43, 44, 53, 42.0 2/8 5/8 0 
>100 
3) (J 2) BN LEW 0.64 mg/kg X 14 9 >100 X 9 >100 0 0 0 
4) (10) BN LEW 0.64 mg/kg X 14, 4 >100 X 4 >100 0 0 0 
then weekly 
5) (12) LEW BN 3 11,12,13 12.0 0 3/3 0 
6 LEW EN 0.15 mg/kg X 14 6 14: 20, 22, 23, 32, 32 22.5 1/6 2/6 3/6 
7) (12) LEW BN 0.64 mg/kg X 14 8 6,b 27,27, 28,"'"29, 30, 36, 36 28.5 1/8 0 7/8 
8 LEW BN 1.0 mg/kg x 14 8 8,b 1MIfDqoIh4M~M~P~ERP 40.0 :3/8 0 4/8 
9 LEW BN 1.0 mg/kg x 14, then 8 8,b 23,b 35, 42, 44, 47, 49, 54 43.0 2/8 0 6/8 
weekly 
10 LEW BN 0.64 mg/kg x 14, 7 27, 30, 34, 44, 62,b 88, 97 1/7 0 6/7 
then rescue with 
1.28 mg/kg x 7 
and 0.64 mg/kg 
there after 
11 LEW BN 0.64 mg/kg continu- 7 33,b 57,b 83,b >91, >100 x 3 3/7 0 0 
ously 
): previously reported. 
"Bold type: temporary GVHD. Underlining: fatal GVHD. 
b Volvulus, distal anastomosis obstruction. 
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TABLE 3. Flow cytometry analysis of donor LEW cells in recipient BN tissue during acute rejection in untreated rats and during late GVHD 
in rats treated with FK506 
Treatment 
None 
FK506 (1.0 mg/kg/day x 14 plus 
weekly) 
Days after 
transplantation 
5 (n = 2) 
9 (n = 2) 
44,54 (n = 2) 
(GVHD) 
* Positive staining was not detectable with mAb 163. 
doses, 17 of 24 rats developed fatal GVHD (groups 7-9, Table 
2). This began with a generalized skin flush at variable times 
after stopping the daily FK506, whether or not weekly treat-
ment was continued (Table 2). Compared with the mean time 
of 1.3 days for onset of GVHD after stopping daily treatment 
with 0.15 mg/kg FK506, the interval was 24 days with the 
highest FK506 dose plus weekly supplementation. The post-
operative weight loss in the treated animals was delayed with 
each increment of therapy, but eventually affected all groups 
(Fig. 2). 
The flushing of GVHD was followed by skin erosion and 
hyperkeratosis, and was reflected in loss of body weight. How-
ever, the severity of the GVHD and the clinical course from its 
onset to death were not predictably related to the treatment 
dosages in individual experiments. Once GVHD was diagnosed, 
the time to death was 2 to 12 days. 
Correlation of GVHD with flow cytometry. Two animals in 
Group 9 (1.0 mg/kg/day FK506 for 2 weeks and weekly there-
after) were sacrificed at 44 and 54 days with obvious GVHD. 
Flow cytometry studies showed donor cells in the blood, spleen, 
and host mesenteric lymph nodes similar to those found in 
untreated intestinal recipients (Table 3). 
Rescue from GVHD. With resumption of delayed daily treat-
ment of BN recipients with 1.28 mg/kg FK506 for 7 days 
followed by reduced daily doses of .64 mg/kg, it was possible to 
reverse the established GVHD (confirmed by ear biopsy) that 
developed after an initial 14-day course of .64 mg/kg/day (group 
10, Table 2). After the development of GVHD and following 
the loss of more than 15% of their body weight, 3 of 7 animals 
had secondary weight gain (Fig. 3), decrease of the skin rash, 
and restoration of hair growth. The remissions lasted for 25 to 
30 days, but the GVHD recurred with a second decrease of body 
weight when the FK506 dose was halved to .64 mg/kg/day, 
causing death 57 and 65 days after rescue. 
Prophylaxis of GVHD. When primary daily treatment with 
0.64 FK506 was continued for 100 days instead of being stopped 
at 14 days, none of the animals showed any clinical sign of 
GVHD or rejection during treatment (group 11, Table 2). 
However, 3 of the 7 rats died under treatment after 33 to 83 
days from volvulus or ileus. 
Cell migration and repopulation. A formal comparison of the 
cell repopulation after BN-to-LEW versus LEW-to-BN intes-
tinal transplantation was made in 15 additional animals treated 
Lymphocytes Recipient Donor phenotype phenotype 
Spleen 93.30±O.71 5.35±1.06 
Blood 91.05±1.63 8.25±1.06 
MLN 94.25±O.49 4.30±O.71 
Spleen 97.35±O.35 O.10±O.14* 
Blood 98.15±O.O7 O.55±0.35* 
MLN 96.40±O.14 0.90±0.14* 
Spleen 95.75±1.77 4.55±3.04 
Blood 95.95±2.65 2.65±1.20 
MLN 96.50±1.98 2.85±2.62 
Days after transplantation 
FIGURE 2. Body weight changes after LEW-to-BN transplantation 
with different dose schedules. FK506 was given for 14 days after 
transplantation in groups 6-9. In group 9, subsequent weekly injections 
were given of FK506 (1 mg/kg: arrow). 
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FIGURE 3. Body weight change of BN recipients of LEW intestine 
(group 10) after G VHD was diagnosed, whose original FK506 treatment 
was 0.64 mg/kg for 14 days. When GVHD developed with a 15% loss 
of weight, FK506 treatment was resumed with 1.28 mg/kg/day for 7 
days, then 0.64 mg/kg/day thereafter. 
for 2 weeks with 0.64 mg/kg/day. Almost all of the lymphocytes 
found in the graft mesenteric lymph nodes could be phenotyped. 
At the end of the first week (during treatment) and for the rest 
of the observation period out to 30-45 days, the lymphocytes 
in the graft were predominantly of recipient phenotype no 
matter in which strain direction the transplants were performed 
(Fig. 4). The percentage of donor lymphocytes in recipient 
blood and lymphoid tissues also was similar in the two strain 
directions (Fig. 5). The greatest donor representation in the 
grafts as well as in the recipient blood, spleen, and lymph nodes 
was in the I-week specimens followed by a gradual decline 
thereafter. However, there was a tendency with the LEW-BN 
combination for greater LEW (donor) representation in all of 
these locations in the specimens collected at 30-45 days (Figs. 
4 and 5). 
Other histopathologic studies (LEW-to-BN). The skin of BN 
recipients with clinical GVHD showed apoptosis and lympho-
cyte infiltration and vacuolization in the basal layer similar to 
the findings in GVHD after bone marrow transplantation (15). 
Phenotypic analysis of the dermal infiltrates revealed many 
donor class II-positive (L-2I-6+) cells. Similar donor cells were 
also detected after 30-45 days in the spleen, host mesenteric 
lymph nodes, and thymus. Donor class II-positive cells in the 
recipient thymus were rare early in the course of GVHD and 
were largely located in the medulla. The number of donor cells 
in the recipient thymus increased as GVHD worsened, but 
remained small in number. These latter observations were 
reported elsewhere (12). 
DISCUSSION 
We have described previously the ease with which BN (RTI n) 
multivisceral and intestinal grafts can be transplanted to LEW 
(RTIl) recipients using a brief induction course of FK506 (10, 
16-18). The difficulty in controlling intestinal rejection in the 
opposite strain direction also was reported before (12) and was 
confirmed in the present experiments. 
A particularly striking example of the ease of BN-to-LEW 
transplantation is with liver transplantation, in which perma-
nent graft survival can be obtained routinely without any 
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FIGURE 4. Donor and recipient phenotypes of graft mesenteric 
lymph node lymphocytes at different times after LEW-to-BN and BN-
to-LEW transplantation under FK506 treatment (0.64 mg/kg/day for 
14 days). 
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FIGURE 5. Percentage of donor cells in recipient peripheral blood, 
spleen, and mesenteric lymph nodes after BN-to-LEW and LEW-to-
BN intestinal transplantation. 
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treatment (9, 19); the same is true with BN-to-ACI and BN-
to-PVG liver transplants (unpublished observations). It is note-
worthy that the control of rejection and achievement of heart 
graft acceptance under immunosuppression also is easier with 
the BN -to-LEW model than the other way around (unpublished 
data). BN may have "universal donor" qualities for heart trans-
plantation in other strain combinations such as BN -to-WAG 
(easy), whereas WAG-to-BN is difficult (20). Why BN should 
be a universal donor is not known. 
An interesting clue is that monoclonal antibody L-21-6, 
which was used in our phenotyping experiments, is anti-LEW 
class II and has been identified as an mAb against the invariant 
chain of class II (unpublished observations). L-21-6 stains 
many rat strains (LEW, ACI, W IF, PVG, and F344) but not 
BN, which may be due to its absence or a change in antigenic 
composition. The invariant chain is involved with intracellular 
transport, assembly, and sorting of MHC class II molecules. It 
is believed that invariant chain and MHC class II molecules 
are assembled after insertion into endoplasmic reticulum of 
antigen-presenting cells (APC), an arrangement that prevents 
the binding of endogenous peptides to these molecules. After 
intracellular transport to the endosomal compartment, the 
invariant chain is degraded and detached from class II mole-
cules. Subsequently, class II polypeptides are charged with 
processed antigen and undergo passage to the cell surface (21, 
22). Thus, the absence or alteration of invariant chain in BN 
rats could explain an ineffective endogenous and exogenous 
antigen presentation pathway through APCs across a wide 
spectrum of recipient strain diversity. 
In addition to donor antigen differences and their presenta-
tion, rejection depends on the recipient's genetically determined 
ability to respond to these differences. Certain rat strains (LEW 
[RTll], W IF [RTI uJ) have been classed as high responders and 
others have been characterized low responders (DA [RTl"], 
PVG [RTI C]) according to their ability upon stimulation to 
produce antibody and CTL (23). Efforts to equate recipient 
responder status to the CD4 population in rats (24-27) and 
mice (28) or to variable dependence of CD8+ cell activation on 
CD4 + cells have provided confusing results. In our studies of 
unaltered animals the lymphoid tissues of LEW rats had sig-
nificantly more T lymphocytes and more CD8+ and fewer B 
cells than the BN rats. The CD4+ population was equal. How-
ever, both strains were well endowed with all subpopulations. 
The one-way MLR with lymphocytes from these animals was 
similar in each direction with or without media enrichment 
with FK506. Thus, our supporting studies in cells from unal-
tered BN and LEW or of cultured cells exposed to FK506 did 
not explain convincingly the disparity of rejection in LEW -to-
BN compared with BN-to-LEW transplantation. 
Even more puzzling was the propensity of intestinal LEW 
grafts to cause GVHD. DeBruin et al. (29) have described 
analogous findings under cyclosporine after WAG (RTlll)-to-
BN but not B N -to-W AG intestinal transplantation. The par-
adox in our experiments was that the LEW intestinal lymphoid 
component was intensely hostile to the whole BN recipient, 
whereas the intact total LEW immune apparatus responded 
benignly to BN intestinal grafts. The severity of the resulting 
GVHD was not what might have been predicted from strict 
extrapolation from Billingham's rules. 
The geographic pattern of graft lymphoid repopulation and 
lymphoid migration from the LEW intestine into the BN host 
could not be used to explain either GVHD or graft rejection in 
the LEW -BN experiments, because it was essentially the same 
as after BN-to-LEW intestinal or multivisceral transplantation 
under FK506 in which neither rejection nor GVHD occur. In 
either strain direction with or without FK506 immunosuppres-
sion, a shower of intestinal lymphocytes left the graft as they 
were replaced by recipient lymphocytes, accounting peripher-
ally for 2 to 10% of the lymphocytes in the blood and major 
lymphoid organs of the host. The migration excepted only the 
thymus, where donor lymphocytes were rare and largely con-
fined to the medulla. The consequent well-tolerated composite 
grafts after BN-to-LEW (10) and human (11) intestinal trans-
plantation, which are made up of donor parenchymal and 
recipient lymphoreticular components, have been described as 
local organ chimeras. 
It would be inappropriate to think ofthe intestinal chimerism 
as "local" if in fact the donor lymphoreticular cells remain 
permanently viable, as seems likely. Ildstad and Sachs have 
demonstrated a state of systemic "mixed" allogeneic (30) and 
xenogeneic (31, 32) chimerism in which rodents conditioned 
with total body or total lymphoid irradiation have been per-
manently constituted with bone marrow grafts of combined 
syngeneic and allogeneic (or xenogeneic) cells. Because these 
stable mixed chimeras accept other tissues and organs from the 
bone marrow donor strains and are highly resistant to GVHD, 
this work has reawakened hope of successful tolerance induc-
tion. 
In view of the lymphoreticular migration and cell repopula-
tion that follows intestinal transplantation, our hypothesis is 
that stable mixed allogeneic chimerism is frequently and acci-
dentally achieved after intestinal or multivisceral transplanta-
tion under immunosuppression both in animals and in man. 
LEW rats with apparent permanent survival of BN intestinal 
or multivisceral grafts are currently being studied to see if 
systemic chimerism exists. If so, it will remain to be explained 
why this state is so easy to achieve with some experimental 
and clinical donor-recipient combinations and so difficult with 
others. 
The circumstances predicting success are unclear. In the 
successful human intestinal transplantations performed so far 
under FK506 or cyclosporine, GVHD has been rare in spite of 
the fact that HLA matching has been random and uniformly 
poor (7, 8). How to identify and avoid bad clinical donor-
recipient combinations analogous to the LEW-to-BN model is 
not evident. Nor is it certain, as has been assumed until 
recently, that iatrogenic efforts to alter the host-graft immu-
nologic balance with antigraft lymphoid procedures will be 
fruitful; there may be unexpected penalties, including the de-
velopment of lymphoproliferative lesions (33). Finally, it was 
shown in the experiments herein reported that even the rela-
tively intractable G VHD of LEW -to-BN transplantation could 
be controlled or even reversed with heavy FK506 immuno-
suppression, which must be continuous. The reversal with 
FK506 of established GVHD also has been demonstrated after 
bone marrow splenocyte transplantation (34). This suggests 
that eventual graft acceptance can be achieved even with "bad" 
donor-recipient combinations. 
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